Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Incidence of Stargardt disease type 1
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of Stargardt disease type 1

1 evidence topic · 1 source

Incidence and prevalence: Netherlands nationwide registry: incidence

“The incidence was 1.67‐1.95:1,000,000 per year” (opens the source at this quote in a new tab)
“with and without 10% of potentially unregistered cases” (opens the source at this quote in a new tab)